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Abstract 
Current first-line antidepressants can take weeks or months to decrease depressive 
symptoms. Low dose ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, 
shows potential for a more rapid antidepressant effect, with efficacy also evident in 
previously treatment-resistant populations. However, a greater understanding of the 
physiological mechanisms underlying such effects is required. We assessed the potential 
impact of ketamine infusion on neurobiological drivers of kynurenine pathway metabolism in 
major depression (HPA axis hyperactivity, inflammation) in patients with treatment-resistant 
depression compared to gender-matched healthy controls. Furthermore, we assessed these 
biomarkers before and after electroconvulsive therapy (ECT), which is currently the gold 
standard for management of treatment-resistant depression. As previously demonstrated, 
treatment with ketamine and ECT was associated with improved depressive symptoms in 
patients. At baseline, waking cortisol output was greater in the ECT cohort, kynurenine was 
greater in the ketamine cohort, and kynurenic acid was less in patients compared to healthy 
controls, although inflammatory markers (IL-6, IL-8, IL-10 or IFN-γ) were similar in patients 
and controls. Furthermore, in patients who responded to ECT, the cortisol awakening 
response was decreased following treatment. Despite a trend towards lesser kynurenine 
concentrations in those who responded to ketamine, ketamine was not associated with 
significant alterations in any of the biomarkers assessed.  
 
Keywords: Depression; ketamine; cortisol; immune; cytokine; kynurenine 
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Introduction 
Major depression is the leading cause of disability in the world (WHO, 2016). Molecular 
biological markers of depression and remission may aid diagnosis, prognosis and prediction 
of which treatment strategies will work best (see Gururajan et al., 2016a, for a review). 
Hypothalamic-pituitary-adrenal (HPA) axis hyperactivity features prominently in the 
neurobiology of depression (Pariante & Lightman, 2008). This dysregulation may be due to 
upregulation of the immune system in depression (e.g. Raison et al., 2006), creating a vicious 
cycle in major depression (Kim et al., 2016). Furthermore, treatment of major depression can 
enhance anti-inflammatory cytokine activity (e.g. Maes et al., 1997; O’Brien et al., 2004; 
Dowlati et al., 2010).   
Altered HPA axis and inflammatory activity may in turn upregulate enzymes which will 
lead to increased metabolism of tryptophan along the kynurenine pathway; indoleamine 2,3-
dioxyegnase (IDO) and tryptophan 2,3-dioxyegnase (TDO) (e.g. Ruddick et al., 2006; 
Badawy, 2017; Cervenka et al., 2017). The kynurenine pathway has been implicated in a 
number of neuropsychiatric as well as neurodegenerative diseases (see O’Farrell & Harkin, 
2017, for a review), and may even play a key role in the etiology of psychiatric disorder 
(Schwarcz & Stone, 2017). In patients with major depression, heightened plasma kynurenine 
levels have been observed (Sublette et al., 2011), and there is also evidence of lowered 
peripheral concentrations of kynurenic acid, a neuroprotective metabolite of kynurenine 
(Myint et al., 2007). The interplay of HPA axis activity, immune system activity and 
tryptophan metabolism provides a unifying neurobiological framework for depression that 
might explain its key symptoms (see Clarke et al., 2017, Kennedy et al., 2017).  
Serotonin has become a major target for treatment of major depression via first-line 
monoaminergic antidepressants such as selective serotonin reuptake inhibitors (e.g. 
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Ramachandraih et al., 2011; cf. Andrews et al., 2015, for an alternative account). However, 
these drugs can take a number of weeks to work, and a substantial proportion of patients do 
not respond (e.g. Trivedi et al., 2006). New pharmacological targets and therapies are thus 
urgently needed (O’Leary et al., 2015). Evidence suggests that ketamine, which affects the 
glutamergic system (see review by Naughton et al., 2014), leads to treatment response in 
treatment-resistant depression (Zarate et al., 2006). However, the side effect profile of 
ketamine, which still requires further research in clinical settings (Short et al., 2017), and 
which necessitates careful patient screening and monitoring (Sanacora et al., 2017), as well as 
the  potential for abuse of the drug (Kalsi et al., 2011), mean that there is a need for safer 
precision therapies. A better understanding of ketamine’s underlying mechanistic effects 
could allow for the development of such treatment options. Furthermore, the antidepressant 
effect of a single ketamine infusion may not persist beyond a week, although repeated 
infusions may maintain these effects for at least 2-3 weeks (Murrough et al., 2013; Singh et 
al., 2016), and so multiple infusions may be given in a clinical context to maintain effects. 
Consequently, a better understanding of the effects of multiple infusions is required. 
The pro-inflammatory cytokine IL-6 was predictive of treatment response to ketamine in 
one study (Yang et al., 2014), though not in a more recent study (Park et al., 2017). There is 
also evidence that ketamine can increase cortisol output in healthy volunteers (from 30 
minutes before and to three hours after ketamine infusion in the morning; Khalili-Mahani et 
al., 2015). However, there is a lack of research examining the impact of ketamine on the 
cortisol awakening response, a key variable in psychoneuroendocrinological research related 
to depression (Stalder et al., 2016). Similarly, there is a paucity of research examining 
treatment effects on kynurenine levels in patients with major depression, although there is 
preclinical evidence indicating that ketamine prevented the development of 
lipopolysaccharide-induced depressive like behaviour, which occurs via the activation of IDO 
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(O’Connor et al., 2009). Indeed, it has been proposed that the kynurenine pathway might 
represent a common target for ketamine with respect to the inflammatory and glutamate 
hypotheses of depression (Miller, 2013).  
In the current research, we examined the neurobiology of major depression via cortisol 
awakening response, plasma cytokine levels (IL-6, IL-8, IL-10, and IFN-γ), and kynurenine 
pathway metabolites. We compared these measures in patients with treatment-resistant major 
depressive disorder to healthy controls. Furthermore, we examined whether these biological 
factors were altered by three infusions of ketamine, compared to electroconvulsive therapy, a 
highly established and well-validated intervention for treatment-resistant depression (UK 
ECT Review Group, 2003).  
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Material and methods 
Ethical approval for this research was obtained from the Clinical Research Ethics 
Committee of the Cork Teaching Hospitals (EMC 3(nn) 08/11/11), which is nationally 
recognised by the Department of Health & Children, Ireland, and the Irish Medicine Board, 
Ireland (now the Health Products Regulatory Authority; IMB: EudraCT number: 2011-
003654-40). The ECT component of this research was approved by the Research Ethics 
Committee of St. Patrick’s Mental Health Services (Protocol No, 21/12). 
Design 
The impact of treatment-resistant depression (TRD) was examined through cross-sectional 
comparisons between patients with TRD and healthy controls. A repeated measures design 
was used to assess the impact of treatment (ketamine or ECT) on biomarkers of depression 
(cortisol awakening response, cytokines and tryptophan/kynurenine pathway metabolites), 
with biomarkers measured before and after treatment. Depressive symptoms were assessed 
using the 17-item Hamilton Depression Rating Scale (HDRS), and patients who showed a 
reduction in their HDRS scores of greater than 50% were classed as responders. 
Participants  
Patients had a current DSM-IV diagnosis of major depressive disorder at the time of the 
clinical trial. Seventeen patients were recruited for the ketamine arm of the trial, which was 
conducted at South Lee Community Mental Health Service in Cork, Ireland. Twenty patients 
with major depressive disorder, currently depressed who were being assessed for ECT were 
recruited at St Patrick’s University Hospital (see Supplementary Table 1 for participant 
demographics). All patients had failed to respond to at least two adequate trials of 
antidepressant medication, as assessed with a modified version of the Antidepressant 
Treatment History Form (Prudic et al., 1990, 1996; Sackheim et al., 1990, 2001). Participants 
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were excluded in the case of any significant physical illness including acute or chronic 
infections, endocrine, immune or metabolic disorder such as autoimmune disorders, 
inflammatory bowel disease, acquired immunodeficiency syndrome, or if they were greater 
than 10% above ideal body weight. In the ketamine arm of the trial, five participants dropped 
out following the first infusion of ketamine and a further two dropped out after the second 
infusion. Two participants dropped out of the ECT arm of the trial prior to completion of 
post-ECT assessment. 
Twenty control participants were recruited from Cork University Hospital staff. Control 
participants were screened for personal or family history (1st degree relative) of mental 
disorder and excluded if positive. All healthy controls were within 10% of ideal body weight. 
Procedure  
Participants received either twice-weekly brief-pulse bitemporal ECT (Semkovska et al., 
2016) or sub-anaesthetic (0.5mg/kg) intravenous infusions of ketamine once a week for up to 
three weeks (see Allen et al., 2015, for detailed information).  
Saliva samples were collected using Salivettes (Sarstedt, Germany); baseline samples were 
collected on the morning prior to study visits, and post-intervention samples were collected 
one week following each ketamine infusion or 4-7 days following the final ECT session. 
Saliva samples were taken upon waking, 30 minutes post waking and 150 minutes post 
waking. Participants were advised to take the first saliva sample as soon as they woke up, and 
not to eat or drink 15 minutes prior to the second or third sample, and not to brush their teeth 
until all samples had been collected. We did not require that participants wake at a specific 
time, but followed their normal routine as closely as possible. Upon receipt of the samples, 
the salivettes or test tubes were immediately centrifuged (3000 rpm for 15 minutes) and the 
saliva collected was transferred to sterile 1.5ml containers and frozen at -80 degrees Celsius. 
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Six millilitre samples of whole blood (fasting) were collected between 8 a.m. and 11 a.m. 
on the morning of ketamine infusion for determination of baseline IL-6, IL-8, IL-10, IFN-γ 
concentrations. Similar samples (non-fasting) were taken two hours after ketamine infusion. 
A fasting sample was taken 24 hours later and one week later in the ketamine cohort. This 
was repeated two hours and one week post ketamine infusion over the second and third 
infusions for participants who received these infusions.  In the ECT cohort, whole blood 
(fasting) was similarly collected between 8 a.m. and 11 a.m. on the morning of ketamine 
infusion for determination of baseline cytokine concentrations. Fasting samples were taken 4-
7 days following the final ECT session. Samples were centrifuged immediately and frozen at 
-80 degrees Centigrade. See Supplementary Figure 1 for timeline of sampling for the 
ketamine and ECT cohort. 
Biochemical analysis 
Cortisol concentrations were measured in saliva using Enzo® enzyme immunoassay 
according to manufacturer's instructions. Assay detection limit was 0.16 nmol/L. Inter and 
intra-assay % C.Vs were 11.24% and 8.2% respectively.  
Measurement of IL-6, IL-8, IL-10, and IFN-γ concentrations were conducted in duplicate 
using MesoScale Discovery custom assays according to manufacturer's instructions. IL-
8: Lower limit of detection = 0.04 pg/ml. Intra-assay CV = 3.6% and inter-assay CV = 7.1%. 
IL-6: Lower limit of detection = 0.06 pg/ml. Intra-assay CV = 4.5% and inter-assay CV = 
7.3%. IL-10: Lower limit of detection = 0.03 pg/ml. Intra-assay CV = 3.7% and inter-assay 
CV = 10.1%. IFN- γ: Lower limit of detection = 0.2 pg/ml. Intra-assay CV = 5% and inter-
assay CV = 9.2%.  
Total tryptophan and kynurenine pathway metabolites were determined as previously 
described (Clarke et al., 2009). Briefly, plasma samples were spiked with internal standard 
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(3-Nitro-l-tyrosine) prior to being deproteinised by the addition of 20 µl of 4 M perchloric 
acid to 200 µl of sample. Samples were centrifuged at 21,000g on a Hettich Mikro 22R 
centrifuge (AGB, Dublin, Ireland) for 20 minutes at 4 °C and 100 µl of supernatant 
transferred to a HPLC vial for analysis on the HPLC system (UV and FLD detection). All 
samples were injected onto a reversed phase Luna 3 µm C18 (2) 150 × 2 mm column 
(Phenomenex), which was protected by KrudKatcher disposable pre-column filters 
(Phenomenex) and SecurityGuard cartridges (Phenomenex). The mobile phase consisted of 
50 mM acetic acid and 100 mM zinc acetate with 3 % (v/v) acetonitrile and was filtered 
through Millipore 0.45-µm HV Durapore membrane filters (AGB) and vacuum degassed 
prior to use. Compounds were eluted isocratically over a 30-min runtime at a flow rate of 
0.3 ml/min after a 20-µl injection. The column was maintained at a temperature of 30 °C, and 
samples/standards were kept at 8 °C in the cooled autoinjector prior to injection. The 
fluorescent detector was set at an excitation wavelength of 254 nm and an emission 
wavelength of 404 nm. The UV detector was set to 330 nm. l-Tryptophan and kynurenine 
were identified by their characteristic retention times as determined by standard injections 
which were run at regular intervals during the sample analysis. Analyte: Internal standard 
peak height ratios were measured and compared with standard injections, and results were 
expressed as nanogram per millilitre of plasma.  
Statistical analysis 
Statistics were calculated using SPSS-18. A p-value of 0.05 was selected as the threshold of 
statistical significance. Graph Pad Prism version 5.0 for windows (Graph Pad Software, San 
Diego, CA, USA, (www.graphpad.com) was used for graph design. Where normality was 
violated, square root or natural log transformations were used as necessary. Area under the 
curve with respect to ground (AUCg) and increase (AUCi) were calculated according to 
guidelines of Pruessner et al (2003). Differences at baseline between patients in the ketamine 
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and ECT cohorts and healthy controls were calculated using ANOVA (with LSD post-hoc 
test). The effect of ketamine or ECT was assessed using either repeated measures ANOVA 
(ketamine) or t-tests (ECT). Furthermore, to assess the relationship between clinical 
symptoms and the biological variables examined, we computed bivariate (Pearson) 
correlations between the change in symptom severity (as measured with the HDRS) and the 
corresponding changes in the biological variables at each timepoint.  
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Results 
Participant characteristics 
The characteristics of the participants group are outlined in Supplementary Table 1. The 
three groups were well matched on gender, although the ECT group were somewhat older 
than the ketamine group and the healthy controls, who were similar to each other in age.  
 
Treatment-resistant depression and assessed biomarkers 
There was no significant difference between patients in the ketamine and ECT cohorts and 
controls in terms of IL-6, IL-8, IL-10 or IFN-γ concentrations. However, salivary cortisol 
output differed between groups (AUCg: F(2, 48) = 4.74, p = .013), and was greater at 
baseline in the ECT cohort compared to either the ketamine cohort (p = .006) or healthy 
controls (p = .018); the ketamine cohort and healthy controls did not differ from each other in 
cortisol levels.  
Plasma kynurenine concentrations differed between groups, F(2, 53) = 3.93, p = .026; it was 
significantly greater in the ketamine cohort compared to both healthy controls (p = .045) and 
the ECT cohort (p = .009), who did not differ from each other. There was a marginally 
significant difference between groups in terms of plasma tryptophan concentrations, F(2, 54) 
= 2.91, p = .063; the ketamine cohort had greater tryptophan levels than the ECT cohort (p = 
.02), while the healthy control group did not differ from either cohort. The groups were 
similar in terms of kynurenine:tryptophan ratio. Kynurenic acid also differed between groups, 
F(2, 28) = 4.93, p = .015, and was lower in both the ketamine (p = .006) and ECT cohort (p = 
.013) compared to the healthy controls, although the two cohorts of TRD patients did not 
differ from each other.  Similarly, the kynurenic acid:kynurenine also differed between 
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groups, F(2, 28) = 13.41, p < .001, and was lower in both the ketamine (p < .001) and ECT 
cohort (p = .036) compared to the healthy controls. 
 
***INSERT FIGURE 1 ABOUT HERE*** 
 
Impact of treatment with ketamine and ECT 
A majority of patients indicated a clinical response (a reduction in HDRS of 50% or more) 
to ketamine at all post-baseline timepoints except for one week following the first infusion. 
Of 17 participants receiving the first ketamine infusion, 13 showed a clinical response at 2 
hours and 24 hours post-infusion, and 7 at one week post-infusion. Of 12 participants 
receiving the second infusion, 12 showed a response at 2 hours post-infusion and 8 at one 
week. Of 10 participants receiving the third infusion, 9 showed a response at 2 hours and 6 at 
one week. Of 18 participants who completed the HDRS following ECT, 9 showed a clinical 
response. 
For the ketamine cohort as a whole, treatment did not affect kynurenine pathway 
metabolism. However, there was a trend towards a decrease in kynurenine concentration in 
ketamine responders at two hours after the first infusion, t(12) = 2.01, p = .067, and a trend 
for a reduced kynurenine/tryptophan ratio at 24 hours following the first infusion, t(11) = 
2.15, p = .054. ECT did not significantly normalise kynurenine pathway metabolism, for the 
ECT cohort as a whole or for responders to ECT intervention. Reduction in depressive 
severity following ketamine/ECT was correlated with increased kynurenic acid at 2 hours 
following the second infusion (r = -1, p = .013), and at one week after the third infusion (r = -
1, p = .005), but there was no consistent pattern of correlation between level of treatment 
response and changes in the kynurenine pathway. 
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***INSERT FIGURES 2 AND 3 ABOUT HERE*** 
 
Ketamine treatment was not associated with a change in the cortisol awakening response. 
Ketamine responders did not have significantly altered cortisol awakening response post-
treatment. ECT treatment did not affect cortisol in the ECT cohort overall, nor was there was 
an impact of ECT treatment on overall salivary cortisol profile. However, the area under the 
curve with respect to increase was significantly lesser following ECT in patients who 
responded to ECT, t(5) = 2.68, p = .044; this is likely due to a highly significant attenuation 
in the cortisol increase between waking and 30 minutes post-waking,  t(5) = 4.41, p = .007. 
Change in depressive severity following ketamine/ECT was not correlated with any change in 
cortisol awakening response. 
 
***INSERT FIGURES 4 AND 5 ABOUT HERE*** 
 
There was no significant change in the immune markers following ketamine treatment or 
ECT treatment for these cohorts as a whole. ECT responders did not show significantly 
altered cytokine levels post-ECT; nor did ketamine responders have any significant 
alterations in any of the cytokines examined. Reduction in depressive severity following 
ketamine/ECT was correlated with higher IL-6 at 24 hours following the first infusion (r = -
0.66, p = .007), and higher IL-8 at two hours after the third infusion (r = -0.64, p = .048), but 
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there was no consistent pattern of correlation between level of treatment response and 
changes in immune markers. 
 
***INSERT FIGURE 6 AND 7 ABOUT HERE*** 
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Discussion 
To the best of our knowledge, this is the first research in patients to examine whether the 
antidepressant effects of ketamine are associated with changes in kynurenine pathway 
metabolism. The cohort of patients receiving ketamine had greater plasma kynurenine 
concentrations at baseline compared to healthy controls, consistent with previous research 
(e.g. Sublette et al., 2011). There was also a trend towards lesser kynurenine concentrations 
two hours after a first ketamine infusion in those patients who responded to ketamine at this 
time, although this was not was not statistically significant; nor was it sustained following 
later infusions. Concentrations of the neuroprotective metabolite kynurenic acid were also 
lower in both cohorts of patients with treatment-resistant depression (consistent with 
Schwieler et al., 2016), although this was not affected by treatment with either ECT or 
ketamine, despite previous evidence suggesting broad changes in the kynurenine pathway 
during ECT (Guloksuz et al., 2015). Other studies have not shown differences between 
depressed patients and controls in tryptophan, kynurenine, or tryptophan: kynurenine ratio 
(Sorgdrager et al, 2017). As ketamine nonetheless reduced depressive severity, the current 
results suggest that resolution of kynurenine pathway activation may not be necessary for 
symptomatic improvement.  However, it will be important in future studies to conduct a more 
comprehensive assessment of kynurenine pathway metabolites that will allow more definitive 
conclusions regarding their role in the pathophysiology and treatment of depression. This 
includes an assessment of the neurotoxic arm of the kynurenine pathway, where the use of 
liquid chromatography or gas chromatography/mass spectrometry may be of particular utility. 
It will also be of interest to determine whether different ketamine protocols have different 
effects on the tryptophan-metabolic pathway, and to what extent this is mediated by the 
immune system or the HPA axis. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Both cohort of patients, as well as the healthy volunteers, displayed an increase in cortisol 
following waking. However, it is notable that only the group that received ECT had either of 
the posited biological conditions leading to increased kynurenine pathway metabolism 
(increased cortisol), but it was the group that received ketamine (who did not differ from 
healthy controls in inflammatory markers or cortisol) that had increased kynurenine. 
Furthermore, both groups of TRD patients had a modest reduction in the kynurenine 
acid:kynurenine ratio, despite their different inflammatory/cortisol profiles. Patients were not 
randomised to the ketamine or ECT arm of the study, and it was not possible to match 
participants on all relevant characteristics; it is possible that the differences in baseline levels 
of cortisol may have influenced treatment responses. Nonetheless, our results suggest that the 
neurobiological abnormality in kynurenine pathway metabolism can be an ongoing effect of 
depression, despite resolution of the biology thought to drive it, and furthermore that the 
inflammatory and HPA axis abnormality can resolve without symptomatic improvement. The 
observed lack of altered cytokine levels is inconsistent with previous evidence of heightened 
pro-inflammatory activity in depressed patients (e.g. Maes et al., 1997; Dowlati et al., 2010). 
The current results may be due to the fact that, due to ethical and recruitment considerations, 
the patients assessed in this study were not treatment-naïve. Antidepressant treatments may 
have already normalised inflammation levels in patients (Köhler et al., 2017) and HPA axis 
activity in the ketamine cohort (Schüle, 2017) when the patients were assessed for the first 
time in the current study. In future research, it would also be of interest to assess the more 
short-term effects of ECT, as a review has suggested that there may be differential short- and 
long-term effects of ECT on immune activity, with a single session leading to immune 
activation, whereas repetitive ECT leads to downregulation (Guloksuz et al., 2014). 
Patients in the ECT cohort had heightened cortisol at awakening, and this was attenuated 
following ECT treatment in those who responded to ECT. However, there was a lack of HPA 
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axis alteration in the ketamine cohort of TRD patients compared to healthy controls. Careful 
adherence to sample timing is important when assessing waking cortisol (see consensus 
guidelines, Stalder et al., 2016). As the ECT cohort were inpatients at the time of salivary 
sampling, sampling could be monitored more closely; it is thus possible that differences in 
the process of sampling may account for some of the observed differences in cortisol output 
in this cohort. Despite the rapid improvement in depressive symptoms in a majority of TRD 
patients following ketamine treatment, symptom improvement following ketamine treatment 
was not associated with changes in waking cortisol or cytokines. Again, we cannot rule out 
that ketamine infusion in treatment-naïve patients may have shown changes in these 
biomarkers, which may have been normalised due to antidepressant treatment.    
Of course, other biomarkers of depression may interact with the effects observed in the 
current work; consistent with other research (e.g. Haile et al., 2014), our group has previously 
demonstrated that treatment-resistant depression is associated with lower peripheral 
concentrations of the neurotrophin brain-derived neurotrophic factor (BDNF), and BDNF 
levels were heightened following a single infusion of ketamine in patients who responded to 
ketamine treatment (Allen et al., 2015). Patients with treatment-resistant depression also had 
altered levels of microRNAs associated with the PI3k-AKt-mTOR signalling pathway 
(microRNAs are small nucleotide sequences that can regulate gene expression at the 
transcriptomic level; see review by O’Connor et al., 2012), although these microRNAs were 
not altered by treatment (Gururajan et al., 2016b). Future work could establish if differences 
in pre-treatment kynurenine levels could help in optimising treatments for patients with 
depression. There is evidence that acute tryptophan depletion can reduce kynurenine as well 
as tryptophan levels (Kennedy et al., 2015), but is also associated with a transient relapse in 
depressive symptoms in people with remitted depression (Booij et al., 2005). The relationship 
between tryptophan metabolism and depressive symptomatology is therefore complex, and 
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the impact of tryptophan metabolites (including serotonin) may differ depending on the 
timeframe over which it is studied (e.g. Andrews et al., 2015). 
It should be acknowledged that major depression is a heterogeneous disorder, and attempts 
to reconceptualise psychiatric disorders such as depression in neurobiological terms may 
allow for better prediction of treatment response to pharmacological intervention (e.g. Insel, 
2014; Kelly et al., 2017). Recent research in patients with major depression has also 
identified biotypes in central nervous system neurophysiology which were predictive of 
responsiveness to treatment with transcranial magnetic stimulation (Drysdale et al., 2017). 
There are encouraging developments in preclinical evidence of ketamine metabolites that 
may be associated with an improved adverse effect profile, although they may act through a 
mechanism other than NMDA receptor inhibition (Zanos et al., 2016); substantial future 
research will be required into their efficacy in humans. Such research, in combination with 
findings on peripheral markers of depression such as plasma concentrations of kynurenine or 
BDNF, may help to better predict treatment to novel treatments such as ketamine, although in 
identifying key biomarkers, we should bear in mind that more extensive work has been 
conducted on more clinically established, slower-acting antidepressants.  
Furthermore, we cannot ignore the possibility that the antidepressant effects of ketamine 
observed in this cohort may be related to factors outside the mechanistically oriented 
biomarkers observed. There is some evidence that the dissociative side effects of ketamine 
may in fact mediate its antidepressant effects (Luckenbaugh et al., 2014). Consequently, in 
addressing questions concerning the mechanisms of ketamine, psychological and subjective 
properties of the drug should not be ignored. Non-pharmacological approaches such as 
mindfulness meditation may be able to tap into similar psychological mechanisms, for 
example by creating a psychological “distance from the self”. Such approaches, which have 
demonstrated positive effect under conditions of chronic stress (e.g. Allen et al., 2017) as 
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well as in anxiety and depression (e.g. Hofmann et al., 2010) may complement novel 
pharmacological therapies such as ketamine (Pradhan et al., 2015).  
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Figure Captions 
Figure 1: Baseline levels in healthy controls, ketamine cohort and ECT cohort of (A). 
plasma IL-6, (B). IL-8, (C). IL-10, (D). IFN- γ, (E). cortisol awakening response, (F). cortisol 
area under the curve with respect to ground (G). cortisol area under the curve with respect to 
increase, (H). plasma kynurenine, (I). plasma tryptophan, (J). kynurenine:tryptophan ratio, 
(K). plasma kynurenine acid, (L). kynurenic acid:kyurenine. 
Figure 2: Ketamine treatment and kynurenine pathway metabolism: (A). plasma kynurenine 
(B). plasma tryptophan (C). kynurenine:tryptophan ratio (D). kynurenic acid (E). kynurenic 
acid: kynurenine ratio for all participants completing three infusion (A-E). (F). Plasma 
kynurenine at baseline and at 2 hours following first infusion in those who responded at this 
timepoint (G). Kynurenine:tryptophan ratio at baseline and at 24 hours following first 
infusion in those who responded at this timepoint. 
Figure 3: ECT treatment and kynurenine pathway metabolism: (A). plasma kynurenine (B). 
plasma tryptophan (C). kynurenine:tryptophan ratio (D). kynurenic acid (E). kynurenic acid: 
kynurenine ratio. 
Figure 4: Ketamine treatment and waking cortisol-in the ketamine cohort as a whole: (A). 
salivary cortisol at each timepoint, (B). area under the curve with respect to ground, (C). area 
under the curve with respect to increase.  
Figure 5: ECT treatment and waking cortisol: in the ECT cohort as a whole: (A). salivary 
cortisol, (B). cortisol area under the curve with respect to ground, (C). cortisol area under the 
curve with respect to increase. (D). area under the curve with respect to ground in ECT 
responders. 
Figure 6: Ketamine treatment and cytokines for participants completing all three infusions: 
(A). plasma IL-6, (B). IL-8, (C). IL-10, (D). IFN- γ.  
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Figure 7: ECT treatment and cytokines: in the ECT cohort as a whole: (A). plasma IL-6, 
(B). IL-8, (C). IL-10, (D). IFN- γ.  
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Research highlights 
• Plasma kynurenine was not altered following successful ketamine response 
• Kynurenic acid was reduced in patients with treatment-resistant depression 
• In patients who responded to ECT, the cortisol awakening response was decreased 
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